1351 GMT - GSK's oncology business has stronger assets than it is credited for and they could make a difference next decade, analysts at Jefferies say in a research note. The U.K. drugmaker has made a number of deals that add revenue potential without putting too much pressure on profitability and it still has room for more over the next few years, according to Jefferies. "The acquisitions of IDRx as well as Nuvalent have added assets to the oncology portfolio that have one thing in common--long duration of therapy plus an ability to move up the treatment cascade," the analysts say. "They are highly profitable assets that should start to contribute to the top-line as the HIV business starts to slow down." Shares fall 1.7%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 17, 2026 09:51 ET (13:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.